Multiple Sclerosis, Relapsing-Remitting
Conditions
Keywords
Multiple Sclerosis, RMS, GA Depot, Multiple Sclerosis, Relapsing-Remitting
Brief summary
A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks
Detailed description
A total of 1016 subjects are planned to be randomized into this study to receive treatment with GA Depot or with matching placebo. During the placebo controlled period (PC period, the first 52 weeks of the study immediately after randomization) subjects will receive either 40mg of GA Depot or matching placebo, IM, once every 4 weeks, for a total of 13 times. Subjects who complete the PC period of the study will be offered to continue into the open label period (OL period) for an additional 52 weeks, in which all subjects will receive 40mg of GA Depot IM once every 4 weeks.
Interventions
DRUGGA Depot
Long acting intramuscular injection of glatiramer acetate, once every 4 weeks
OTHERPlacebo
IM injection once every 4 weeks
Sponsors
Mapi Pharma Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
During the placebo controlled period subjects will receive either 40mg of GA Depot or matching placebo, IM, once every 4 weeks, for a total of 13 times. Subjects who complete the PC period of the study will be offered to continue into the open label period for an additional 52 weeks, in which all subjects will receive 40mg of GA Depot IM once every 4 weeks.
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
1. Adult subjects between 18-55 years of age, inclusive. 2. Subjects able to provide signed written informed consent. 3. Subjects must be willing and able to comply with the protocol requirements for the duration of the study. 4. MS diagnosis fulfilling the 2017 McDonald Criteria. 5. Subjects should be ambulatory with an EDSS score of 0-5.5 at screening and baseline visits. EDSS score will be determined by a separate, blinded trained EDSS rater. 6. Subjects should be relapse free and neurologically stable from one month before screening visit and from screening visit to baseline visit. 7. No systemic corticosteroid treatment or ACTH within one month prior to screening visit. 8. Subjects must have experienced at least one of the following: i. At least one documented relapse in the 12 months prior to screening. ii. At least two documented relapses in the 24 months prior to screening. iii. One documented relapse between 12 and 24 months prior to screening, with at least one documented T1-Gd enhancing lesion in MRI performed within 0-12 months before screening. 9. Women capable of child bearing must have a negative urine pregnancy test at screening and baseline visit and use an adequate contraceptive method throughout the study.
Exclusion criteria
1. Use of experimental / investigational drug, and / or participation in drug clinical studies within the 6 months prior to screening. 2. Any off-label drug use for MS treatment such as high dose simvastatin and biotin within 6 months prior to screening. 3. Previous use of immunosuppressant including Mitoxantrone, Alemtuzumab, Cladribine or any other cytotoxic agent within 5 years. 4. Previous use of Natalizumab or any anti-B cell agent within 9 months prior to screening. 5. Previous use of Fingolimod or any other sphingosine-1-phosphate receptor modulator, Dimethyl Fumarate, Diroximel Fumarate (DRF), or Monomethyl fumarate within 2 months prior to screening. Subjects will be excluded if they do not have a lymphocyte count of above 1,000/mm3 at screening. 6. Previous use of Teriflunomide within 12 months if no accelerated elimination procedure was used. 7. Previous treatment with immunomodulators (including IFNβ 1a and 1b, and IV Immunoglobulin (IVIg) within 2 months prior to screening. 8. Previous use of GA or any other glatiramoid. 9. Chronic (more than 30 consecutive days) systemic (IV, PO or IM) corticosteroid treatment within 6 months prior to screening visit. 10. Previous total body irradiation or total lymphoid irradiation. 11. Previous stem-cell treatment, autologous bone marrow transplantation or allogeneic bone marrow transplantation. 12. Subjects with a clinically significant or unstable medical, psychiatric, or surgical conditions that would preclude safe and complete study participation, as determined by medical history, physical exams, ECG and/or abnormal laboratory tests; and or subjects with an increased risk of serious Covid-19 related morbidity. Such conditions may include hepatic, renal or metabolic diseases, systemic disease, acute infection, current malignancy, or recent history (5 years) of malignancy, major psychiatric disorder, history of drug and/or alcohol abuse and allergies that could be detrimental according to the investigator's judgment. 13. Subjects who have \>10 T1-Gd enhancing lesions at screening. 14. A known history of sensitivity to Gadolinium. 15. Inability to successfully undergo MRI scanning. 16. Pregnant or breast-feeding women. 17. Abnormal renal function. 18. Abnormal liver function. 19. History of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study article (e.g., GA, Polyglactin, PVA). 20. Positive testing or a history of positive testing for syphilis, HIV, hepatitis, or tuberculosis. 21. Known or suspected history of drug or alcohol abuse. 22. Subjects diagnosed with any systemic autoimmune disease (other than MS) that may impact the CNS with MS like lesions such as Sarcoidosis, Sjögren's syndrome, Systemic Lupus Erythematosus (SLE), Lyme disease, Antiphospholipid antibodies (APLA) syndrome, etc. Subjects with stable local/organ autoimmune disease such as psoriasis, cutaneous lupus erythematosus, thyroiditis (Hashimoto's, Grave's) etc. may be considered eligible upon the investigator's discretion. 23. Any CNS disorder other than MS that may jeopardize the subject's participation in the study. 24. Subjects with uncontrolled diabetes. 25. Subjects with clotting disorders or receiving treatment with anticoagulants.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Annualized Relapse Rate (ARR) | 52 weeks | ARR during the 52 weeks of the PC period as derived from the total number of confirmed relapses |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Brain MRI (Number of T1 Lesions) | 52 weeks | Cumulative number of new enhancing lesions on T1-weighted images as compared to baseline. |
| Changes in Brain MRI (Number of T2 Lesions) | 52 weeks | Cumulative number of new or newly enlarging hyperintense T2 lesions as compared to baseline. |
| Hyperintense T2-lesion Volume Change | 52 weeks | Change from baseline to Week 52 in hyperintense T2-lesion volume. |
| Enhancing T1-lesion Volume Change | 52 weeks | Change from baseline to Week 52 in enhancing T1-lesion volume. |
Countries
Belarus, Bosnia and Herzegovina, Bulgaria, Estonia, Georgia, Israel, Moldova, Russia, Ukraine, United States
Contacts
STUDY_DIRECTORLaura Popper, MD
Mapi Pharma Ltd.
PRINCIPAL_INVESTIGATORAaron E. Miller, Prof. MD
Mount Sinai School of Medicine, New York, US
Participant flow
Recruitment details
A total of 1108 participants were screened in this study, and 92 participants failed screening. Of these, 92 did not meet eligibility criteria.
Pre-assignment details
1016 participants were enrolled and randomized in the placebo-controlled (PC) double-blind period. Participants were randomized 1:1 to the treatment arms
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 36.7 Years STANDARD_DEVIATION 9.08 |
| Body Mass Index (BMI) | 24.07 kg/m^2 STANDARD_DEVIATION 4.61 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 501 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 5 Participants |
| Number of T1 Enhancing Lesions at Baseline | 1.21 Lesions STANDARD_DEVIATION 2.11 |
| Number of T2 hyperintense lesions at Baseline | 41.10 Lesions STANDARD_DEVIATION 26.97 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 1016 Participants |
| Sex: Female, Male Female | 361 Participants |
| Sex: Female, Male Male | 147 Participants |
| Time from Onset of MS Symptom | 6.94 Years STANDARD_DEVIATION 6.45 |
| Time since date of RMS diagnosis | 4.76 Years STANDARD_DEVIATION 5.52 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 508 | 2 / 508 | 0 / 347 | 0 / 416 |
| other Total, other adverse events | 320 / 508 | 230 / 508 | 107 / 347 | 139 / 416 |
| serious Total, serious adverse events | 24 / 508 | 9 / 508 | 4 / 347 | 10 / 416 |
Outcome results
None listed